Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors by Amanda J.W. Gibson, BSc (Hons), Adrian Box, MD, PhD, Michelle L. Dean, BSc, Anifat A. Elegbede, MSc, Desiree Hao, MD, Randeep Sangha, MD, D. Gwyn Bebb, BMBCh, PhD

Get full text